Raxar (grepafloxacin)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company:

Approval Status:

Approved November 1997

Specific Treatments:

chronic bronchitis

Find Related Trials for The Following Conditions

General Information

Raxar (grepafloxacin) has been approved for mild to moderate cases of acute bacterial exacerbations of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis; for community-acquired pneumonia caused by the same bacteria as well as Mycoplasma pneumoniae; for uncomplicated gonorrhea caused by Neissaria gonorrhoeae; and for nongonococcal urethritis and cervicitis caused by Chlymidia trachomatis.

Raxar tablets are contraindicated in patients with hepatic failure.

Side Effects

Adverse reactions for a multiple-dose regimen of Raxar 600 mg include a 15.8% incidence of nausea, 17.8% of taste perversion, 5.7% of vomiting, 5.4% of dizziness, 4.2% of diarrhea, and 2.2% of constipation.